Prognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis

Cancer Imaging. 2015 Nov 20;15:19. doi: 10.1186/s40644-015-0055-z.


Background: The role of 18-fluorodeoxyglucose positron emission tomography CT ((18)FDG PET/CT), as a prognostic factor for survival in colorectal cancer patients with liver metastases, is still controversial. We sought to perform a meta-analysis of the literature to address this issue.

Methods: A systematic literature search was performed to identify the studies that associated (18)FDG PET/CT to clinical survival outcomes of patients with liver metastases. Methodological qualities of the included studies were also assessed. The summarized hazard ratio (HR) was estimated by using fixed- or random-effect model according to heterogeneity between trails.

Results: By analyzing a total of 867 patients from 15 studies, we found that PET/CT for metabolic response to the therapy was capable of predicting event-free survival (EFS) and overall survival (OS) with statistical significance, and the HR was 0.45 (95% confidence interval [CI], 0.26-0.78) and 0.36 (95% CI, 0.18-0.71), respectively. Furthermore, pre-treatment (18)FDG PET/CT with high standardized uptake value (SUV) was also significantly associated with poorer OS HR, 1.24; (95% CI, 1.06-1.45). However, we did not find a statistically significant effect of post-treatment SUV for predicting OS HR, 1.68; (95% CI, 0.63-4.52).

Conclusions: The present meta-analysis confirms that (18)FDG PET/CT is a useful tool to help predict survival outcomes in patients with liver metastases.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Colorectal Neoplasms / pathology*
  • Fluorodeoxyglucose F18
  • Humans
  • Liver Neoplasms / diagnosis*
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / secondary
  • Positron-Emission Tomography*
  • Prognosis
  • Radiopharmaceuticals
  • Survival Analysis
  • Tomography, X-Ray Computed*


  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18